Argenx stock rating cut to Hold ahead of the Xetra open
Published on 10/26/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRating action and company focus
- Wall Street Zen cut one rating from Buy to Hold.
- The action was issued on October 25, 2026.
- Argenx stock trades pre-market at EUR 783.40 at 8:19 a.m. CET at Lang & Schwarz on October 26, 2026.
Wall Street Zen downgraded argenx from Buy to Hold in a report issued on October 25, 2026. MarketBeat attributed the rating change to Wall Street Zen.
Rating change ahead of the open
The report described the move as a change from a Buy rating to Hold. MarketBeat also listed Wells Fargo as maintaining an Overweight rating while lowering its target price in a separate research note dated October 23, 2026. Those analyst actions are separate from the pre-market price indication.
Lang & Schwarz before Xetra
Argenx stock trades pre-market at EUR 783.40 at 8:19 a.m. CET at Lang & Schwarz on October 26, 2026. The bid was EUR 781.00 and the ask was EUR 785.80. The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of Argenx stock.
Immunology business and investor resources
argenx develops and commercializes immunology therapies for patients with severe autoimmune diseases. Its investor site provides access to financial reports, stock information, events and shareholder-meeting materials. argenx identifies the company’s approved immunology products and investor resources.
Market context: Market report AEX.
